Teva launches generic Ortho Tri-Cyclen Lo for birth control

JERUSALEM – Teva Pharmaceutical Industries on Tuesday announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States. Teva’s Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets, USP) is an oral contraceptive, available in a 28-day blister pack dispenser, used by women to prevent pregnancy.

 

Ortho Tri-Cyclen Lo (norgestimate/ethinyl estrdiol) tablets, marketed by Janssen Pharmaceuticals, had annual sales of approximately $488 million in the United States, according to IMS data as of October 2015.

 

Tri-Lo-Sprintec is indicated for use by females of reproductive potential to prevent pregnancy.